Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer

Revista Espanola de Medicina Nuclear e Imagen Molecular

Volumn 32, Issue 5, 2013, Pages 286-289

  Moslehi, M ^a   Cheki, M ^b   Salehi Marzijarani, M ^c   Amuchastegui, T ^d   Gholamrezanezhad, A ^d,e  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d YALE NEW HAVEN HOSPITAL   (United States)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Asymptomatic; Bone scintigraphy; Diagnostic value; Prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER PATIENT; GAMMA CAMERA; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ASINTOMÁTICO; ASYMPTOMATIC; BONE SCINTIGRAPHY; CÁNCER DE PRÓSTATA; DIAGNOSTIC VALUE; GAMMAGRAFÍA ÓSEA; PROSTATE CANCER; VALOR DIAGNÓSTICO;

ADENOCARCINOMA; AGED; ALKALINE PHOSPHATASE; ASYMPTOMATIC DISEASES; BONE NEOPLASMS; EARLY DETECTION OF CANCER; HUMANS; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM GRADING; NEOPLASM PROTEINS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M MEDRONATE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TUMOR MARKERS, BIOLOGICAL; WHOLE BODY IMAGING;

EID: 84883292865     PISSN: 2253654X     EISSN: 22538070     Source Type: Journal    
DOI: 10.1016/j.remn.2013.01.002     Document Type: Article

References (19)

1. Ritenour C.W.M., Abbott J.T., Goodman M., Alazraki N., Marshall F.F., Issa M.M. The utilization of gleason grade as the primary criterion for ordering nuclear bone scan in newly diagnosed prostate cancer patients. ScientificWorldJournal 2009, 9:1040-1045.
2. Kindrick A.V., Grossfeld G.D., Stier D.M., Flanders S.C., Henning J.M., Carroll P.R. Use of imaging tests for staging newly diagnosed prostate cancer: trends from the CaPSURE database. J Urol 1998, 160:2102-2106.
3. Cooperberg M.R., Lubeck D.P., Grossfeld G.D., Mehta S.S., Carroll P.R. Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor. J Urol 2002, 168:491-495.
4. Al-Ghazo M.A., Ghalayini I.F., al-Azab R.S., Bani-Hani I., Barham A., Haddad Y. Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? A retrospective study. Int Braz J Urol 2010, 36:685-691.
5. American Urological Association: Prostate-Specific Antigen - Best Practice Statement: 2009 Update. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/mainreports/psa09.pdf.
6. Forman J.D., Lee W.R., Roach M., Perez C.A., Beyer D.C., Blasko J.C., et al. Staging evaluation for patients with adenocarcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000, 215(Suppl.):1373-1382.
7. EAU Guidelines; 2010. http://www.uroweb.org/guidelines/.
8. NCCN Clinical Practice Guidelines in OncologyTM, Prostate Cancer Early Detection V.2.2010. http://www.nccn.org/.
9. Briganti A., Passoni N., Ferrari M., Capitanio U., Suardi N., Gallina A., et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol 2010, 57:551-558.
10. Tanaka N., Fujimoto K., Shinkai T., Nakai Y., Kuwada M., Anai S., et al. Bone scan can be spared in asymptomatic prostate cancer patients with PSA of <=20ng/ml and Gleason score of <=6 at the initial stage of diagnosis. Jpn J Clin Oncol 2011, 41:1209-1213.
11. Albertsen P.C. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol. Austria J Urol 2002, 168:880-881.
12. Bartsch G., Horninger W., Klocker H., Reissigl A., Oberaigner W., Schönitzer D., et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001, 58:417-424.
13. Cooperberg M.R., Cowan J., Broering J.M., Carroll P.R. High-risk prostate cancer in the United States, 1990-2007. World J Urol 2008, 26:211-218.
14. Prando A. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. Int Braz J Urol 2004, 30:341-342.
15. Abuzallouf S., Dayes I., Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 2004, 171(6 Pt 1):2122-2127.
16. Pal R.P., Thiruudaian T., Khan M.A. When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer?. Asian J Androl 2008, 10:890-895.
17. Rasch-Isla Munoz A., Catano Catano J.G. Usefulness of bone-specific alkaline phosphatase for bone metastases detection in prostate cancer. Arch Esp Urol 2004, 57:693-698.
18. Kosuda S., Yoshimura I., Aizawa T., Koizumi K., Akakura K., Kuyama J., et al. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer 2002, 94:964-972.
19. Brimo F., Schultz L., Epstein J.I. The value of mandatory second opinion pathology review of prostate needle biopsy interpretation before radical prostatectomy. J Urol 2010, 184:126-130.